WholeAustin · Austin metro · Life Sciences
The complete Austin guide to life sciences — the local businesses and the firms that shape the market, each read for how findable it is online, alongside the concepts, the news and the questions that define the field. Own one? See where you stand and exactly what to improve.
5 local life sciences businesses, each graded on the nine things that decide whether a customer or an AI assistant can find and trust them. Open any name for the full write-up and the specific fixes.
| Business | Area | Site score |
|---|---|---|
| Pecan Street Inc.www.pecanstreet.org | Austin | 802 to fix |
| AlphaRose Therapeuticswww.alpharose.com | Austin | 763 to fix |
| Any Lab Test Nowwww.anylabtestnow.com/round-rock-78681 | Round Rock | 723 to fix |
| Clinical Pathology Laboratorieswww.cpllabs.com | Austin | 624 to fix |
| Sonic Reference Laboratorywww.sonichealthcareusa.com | 624 to fix |
70+ solid 45–69 gaps under 45 costing customers
1 Austin life sciences businesses we could find no website for — each one invisible to everyone searching online right now. Listed as opportunity, never scored. Is one of these yours? Get online →
1 Austin life sciences businesses that have a website which blocked our scanner — common when a site filters datacenter traffic, and not a sign the site is broken. Listed with their site; a blocked site is never scored zero.
The firms, funds and institutions that set the terms in life sciences — context, not local listings; never scored.
The single highest-stakes pillar: which pathway a product travels (510(k), De Novo, PMA, IND-to-NDA/BLA, IVD clearance, LDT), what the resulting labeling permits, and the difference between a cleared claim, an investigational claim and marketing copy that creates regulatory exposure. Every other content decision in this cluster inherits from this one.
Preclinical through Phase IV — endpoints, powering, randomization and blinding, adaptive and platform designs, interim analyses, DSMBs, protocol amendments, site selection and enrollment. This is where a therapeutic's entire value is created or destroyed, and it is what sophisticated buyers and investors read first.
IVDs, laboratory developed tests, molecular and immunoassay platforms, companion diagnostics, CLIA and CAP operations, analytical and clinical validation, sensitivity/specificity/LOD, and the RUO-versus-clinical labeling line. Austin's molecular-diagnostics base makes this a local strength as well as a content pillar.
Design control, verification and validation, human factors, biocompatibility, sterilization, IDE studies, unique device identification, post-market surveillance and MDR reporting — plus the hospital value-analysis committee process that actually decides whether a device gets bought.
Target identification and validation, hit-to-lead and lead optimization, structure-based and computational design, ADME/tox, animal models and their limits, and the modality choice — small molecule, biologic, cell, gene, RNA, ADC — that determines cost, timeline and regulatory route.
GMP manufacturing, tech transfer and scale-up, fill-finish capacity, single-use versus stainless, cold chain and cryogenic logistics, dual sourcing, raw-material qualification, and how a company chooses between building capacity and buying it from a CDMO.
QMS and ISO 13485, 21 CFR Part 820 and the Quality Management System Regulation, GxP across GLP/GCP/GMP, 21 CFR Part 11 and data integrity, CAPA, audits and inspections, Form 483s and warning letters, recall classification, and supplier qualification.
The step most technical founders underestimate: CPT/HCPCS coding, coverage determinations, coverage with evidence development, formulary placement and tiering, prior authorization, gross-to-net, and health-economic dossiers. A cleared product with no code and no coverage has no market.
Out-licensing and in-licensing, option-to-license, upfronts, development and sales milestones, royalty stacking, co-promotion, territory splits, and the diligence a partner runs on your data package. Also freedom-to-operate and the patent estate that makes a deal possible.
SBIR/STTR, NIH and BARDA awards, CPRIT product-development and recruitment grants, venture and crossover rounds, milestone-based tranches, and the tradeoffs between dilutive and non-dilutive money at each stage.
Launch sequencing, KOL engagement, medical science liaisons and the firewall between medical and commercial, advisory boards, speaker programs and their Anti-Kickback exposure, Sunshine Act reporting, sales-force sizing and specialty pharmacy or distributor channels.
ELN and LIMS, EDC and eTMF, regulatory information management, real-world data and evidence, multi-omics pipelines, and machine learning across target discovery, protein structure, trial design and manufacturing — including the unsettled question of what evidence regulators will accept from a model.
CPRIT funding and recruitment, Dell Medical School and UT Austin research commercialization, the Austin Technology Incubator's bioscience track, the molecular-diagnostics lineage from Luminex and Asuragen, lab space and cleanroom availability, and how Austin relates to Houston's Texas Medical Center and San Antonio's research base.
Hiring regulatory affairs, quality, clinical operations and manufacturing science staff in a market that competes with Boston and San Diego; wet-lab and BSL-rated space, cleanroom build-out cost and timeline, and the incubator-to-own-facility progression.
Sponsored research agreements, material transfer agreements, university licensing terms, Bayh-Dole obligations and march-in rights, founder equity and conflict-of-interest management, and how a company works with an academic medical center without inheriting its timelines.
Peer-reviewed publication strategy, congress abstracts and posters, medical writing, fair balance in promotional material, the difference between a scientific-exchange communication and a promotional one, and how to build a claims matrix every piece of content traces back to.
explain substantial equivalence to a predicate, the De Novo route for novel low-to-moderate risk devices with no predicate, and PMA's independent demonstration of safety and effectiveness -- and that the pathway sets what may later be claimed
cleared refers to 510(k) clearance, approved to PMA or a drug approval; say plainly that using them interchangeably in marketing copy is a misbranding risk, not a style choice
an RUO product is not for use in diagnostic procedures; explain that claims, sales practices and even support materials suggesting clinical use can convert it into an unapproved device in FDA's view
explain that FDA's 2024 final rule bringing LDTs under device regulation was vacated in full by a federal court in March 2025, so LDTs remain regulated primarily through CLIA -- and that the policy question is unresolved rather than settled
CLIA regulates the laboratory performing testing; FDA regulates the test as a product -- a lab can be fully CLIA-certified running a test that has no FDA clearance at all
explain that a clinician may prescribe off-label but the manufacturer's promotion is limited to the approved or cleared labelling, and that the limit applies to sales decks, conference booths and website copy alike
explain that benefit claims must be accompanied by comparable presentation of risk information, and that the requirement follows the claim into every format including social posts
define it as a test required to select patients for a specific therapy, usually co-developed and co-labelled, and note the commercial consequence -- the diagnostic's fate is tied to the drug's
research and clinical execution versus development and manufacturing; explain that many sponsors use both and that the contracts and risks are entirely different
distinguish process designations that add FDA interaction from accelerated approval's surrogate-endpoint basis with confirmatory-trial obligations, and warn that designation is not approval and must not be marketed as though it were
describe the documented loop -- user needs, design inputs, outputs, verification, validation, transfer, design history file -- and that it is the first thing an inspector asks to see
a 483 lists an investigator's observations at the close of an inspection; a warning letter is the agency's formal position after review -- explain what each means for a customer doing supplier diligence
no -- explain highly similar rather than identical, the analytical and clinical comparison required, and the separate question of interchangeability
analytical validation shows the assay measures the analyte reliably -- precision, LOD, interference; clinical validation shows the result means something for the patient; a test can pass the first and fail the second
this depends on the specific intended use, risk classification and whether a predicate exists; explain how classification is determined and recommend a pre-submission with FDA rather than guessing in public
explain that a comparative performance claim needs head-to-head data on the same samples under a defined protocol and must be consistent with cleared labelling; describe the evidence required and refuse to bless the claim in the abstract
Get your free website score and the exact list of what to fix — no charge, no pitch. Claim your listing or ask for the full report.